PMID: 9435926Jan 22, 1998Paper

Pharmaceutical aspects of docetaxel

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
M A Kraynak

Abstract

Clinical trials, pharmacokinetics, and pharmaceutical aspects of docetaxel are reviewed. In Phase I trials, the maximum tolerated dose of docetaxel ranged from 80 to 115 mg/m2. The main dose-limiting toxicity was brief neutropenia. These results led to a recommended dosage schedule in Phase II trials of 100 mg/m2 given by i.v. infusion over one hour every three weeks. Docetaxel exhibits linear pharmacokinetics and has an elimination half-life of about 12 hours. Patients with hepatic dysfunction have higher drug concentrations and more severe adverse effects. The overall response rate in Phase II trials in women with anthracycline-resistant breast cancer was 47%. Docetaxel is indicated for use in the treatment of locally advanced or metastatic breast cancer that has progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy. Docetaxel is commercially available as 20- and 80-mg formulations, but both yield the same drug concentration (10 mg/mL) when mixed with diluent. The actual drug concentration in each vial and the volume of diluent differ from those indicated on the vial labels to allow a final concentration of 10 mg/mL in the premixed solution, despite drug loss during preparation....Continue Reading

Citations

Jun 25, 2003·Expert Review of Anticancer Therapy·Tomasz M BeerKristine M Eilers

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
R M Tankanow
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
A LortholaryE Gamelin
© 2021 Meta ULC. All rights reserved